Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma
Saurabh Zanwar(Mayo Clinic), Shaji Kumar(Mayo Clinic), David Dingli, Francis K. Buadi, Morie A. Gertz(Medical University of South Carolina), Nelson Leung(WinnMed), Dragan Jevremović(Mayo Clinic in Arizona), Robert A. Kyle(Mayo Clinic), Prashant Kapoor, Amie Fonder, Moritz Binder(Mayo Clinic in Arizona), Yi L. Hwa, Rahma Warsame, S. Vincent Rajkumar(WinnMed), Wilson I. Gonsalves(Mayo Clinic in Arizona), Taxiarchis Kourelis(Mayo Clinic in Arizona), Martha Q. Lacy(Mayo Clinic), Eli Muchtar(Mayo Clinic), Yi Lin, Suzanne R. Hayman, Angela Dispenzieri(Mayo Clinic), Miriam Hobbs, Matthew Ho(Mayo Clinic)
Cited by 56
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k